NYSE : ENOV

Enovis Corporation

$30.26 USD

$0.74 (2.51%)

Volume
923.45K
Average Volume
1.16M
Market Capitalization
$1.74B
P/E Ratio
-1.51
Dividend Yield
0.00%
Price Target
$41.50
Year High
$34.28
Year Low
$19.14
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$2.04
Company Overview

NYSE

Damien McDonald

Medical - Devices

Healthcare

ENOV

7802

US

USD

302 252 9190

194014502

0001420800

Liquidity Metrics

0.96

2.04

1.05

0.05

0.00

Sales & Valuation

$2.25B

0.76

1.16

48.49

0.63

Profitability

-$20.86

-$1.18B

-49.91%

-48.34%

-60.13%

-29.68%

P/E Metrics

-1.51

0.02

0.02

Analyst Price Target & Rating

$41.50

$52.00

$29.00

Strong Sell

1/5

13 Analysts

-27.08%

Financial Health Scores

-0.21

4/9

$631.02M

$3.83B

$2.35B

-$1.04B

Key Metrics (TTM)

$3.08B

1.35

-4.11

2.04

-60.13%

1.87%

-67.83%

2.11%

215 days

Company Executives
Name Title
Patricia A. Lang Advisor
Oliver Engert Chief Administrative Officer
John Kleckner Vice President, Controller & Chief Accounting Officer
Kyle William Rose Vice President of Investor Relations
Louie Vogt Group President of Reconstructive
Phillip Benjamin Berry Senior Vice President & Chief Financial Officer
Terry Ross Group President Prevention & Recovery
Laura Singleton Senior Vice President & Chief Human Resources Officer
Damien McDonald Chief Executive Officer & Director
Bradley J. Tandy Senior Vice President & Chief Legal Officer
Poll Results

No votes yet today — be the first to share your view!

About Enovis Corporation (NYSE:ENOV) Stock

Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulat ... ors for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.

Enovis Corporation $ENOV Shares Bought by Allspring Global Investments Holdings LLC

2026-07-21 03:07:45

Allspring Global Investments Holdings LLC grew its holdings in shares of Enovis Corporation (NYSE: ENOV) by 38.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,045,360 shares of the company's stock after purchasing an additional 287,687 shares during

Enovis to Host Second Quarter 2026 Results Conference Call on August 6th

2026-07-17 08:00:00

Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2026 financial results on Thursday, August 6th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com.

Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

2026-07-13 08:30:00

DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation veterinary PBM laser therapy system from its Companion Animal Health business. CT-RevitL delivers enhanced clinical performance, greater mobility and a more intuitive treatment experience for veterinary teams and their patients.

4 Top Growth Stocks Worth Buying Under $100 Today

2026-07-03 08:30:00

These four under-the-radar stocks are built to benefit from powerful secular trends that could reward patient, long-term investors.

Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens

2026-06-08 08:30:00

The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis

ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now?

2026-05-22 20:08:46

Enovis develops orthopedic and rehabilitation devices for healthcare providers, serving a broad spectrum of musculoskeletal patient needs.

Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?

2026-05-13 10:55:28

The average of price targets set by Wall Street analysts indicates a potential upside of 65.5% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Enovis Q1 Earnings Call Highlights

2026-05-10 04:07:33

Enovis NYSE: ENOV reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.

Frequently Asked Questions

What is the current Enovis Corporation (ENOV) stock price?

Enovis Corporation(NYSE:ENOV) stock price is $30.26 in the last trading session. During the trading session, ENOV stock reached the peak price of $34.28 while $19.14 was the lowest point it dropped to. The percentage change in ENOV stock occurred in the recent session was 2.51% while the dollar amount for the price change in ENOV stock was $0.74.

ENOV's industry and sector of operation?

The NYSE listed ENOV is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of ENOV?

Patricia A. Lang | Advisor
Oliver Engert | Chief Administrative Officer
John Kleckner | Vice President, Controller & Chief Accounting Officer
Kyle William Rose | Vice President of Investor Relations
Louie Vogt | Group President of Reconstructive

How many employees does ENOV have?

Number of ENOV employees currently stands at 7802. ENOV operates from 2711 Centerville Road, Wilmington, DE 19808, US.

Link for ENOV official website?

Official Website of ENOV is: https://www.enovis.com

How do I contact ENOV?

ENOV could be contacted at phone #302 252 9190 and can also be accessed through its website. ENOV operates from 2711 Centerville Road, Wilmington, DE 19808, US.

How many shares of ENOV are traded daily?

The average number of ENOV shares traded daily for last 3 months was 1.16M.

What is the market cap of ENOV currently?

The market value of ENOV currently stands at $1.74B with its latest stock price at $30.26